← Eichor
Condition: Lupus Nephritis Ln Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lupus Nephritis Ln

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Biomarker Development for Autoimmune Disorders Involving the Kidneys
Phase N/A · 1 location(s) · Oslo University Hospital · NCT07666711A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/Phase 2 · 19 location(s) · Nkarta, Inc. · NCT06557265A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Phase 2 · 12 location(s) · Autolus Limited · NCT07053800Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With
Phase 2 · 17 location(s) · Shanghai Henlius Biotech · NCT07038382A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Phase 1 · 1 location(s) · Hinge Bio · NCT07491900The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Phase 4 · 1 location(s) · Ahmed Yehia Ismail · NCT07700940Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Phase N/A · 7 location(s) · GlaxoSmithKline · NCT06527872Dapagliflozin in Active Lupus Nephritis
Phase 4 · 2 location(s) · Brigham and Women's Hospital · NCT07323524Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
Phase 2 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07363460CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947460Safety and Efficacy of ONT01 in Lupus
EARLY_Phase 1 · 1 location(s) · Hospital for Special Surgery, New York · NCT07107659High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
Phase N/A · 1 location(s) · First Affiliated Hospital, Sun Yat-Sen University · NCT06682507A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236762Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NA · 1 location(s) · Tongji Hospital · NCT06902844The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patien
Phase 2 · 1 location(s) · Nanjing University School of Medicine · NCT07340463A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06943937Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants
Phase 3 · 41 location(s) · Novartis Pharmaceuticals · NCT06711887Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06434363Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06585514Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Phase 4 · 8 location(s) · Peking Union Medical College Hospital · NCT07719140Research Accelerated by You Lupus Registry
Phase N/A · 1 location(s) · Lupus Foundation of America · NCT06927219
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.